Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: An in vitro study

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 9, 2004, Pages 1081-1088

  Ashokraj, Y ^a   Agrawal, S ^a   Varma, M V S ^a   Singh, I ^a   Gunjan, K ^a   Kaur, K J ^a   Bhade, S R ^a   Kaul, C L ^a   Caudron, J M ^b   Pinel, J ^b   Panchagnula, R ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b MÉDECINS SANS FRONTIÈRES   (Belgium)

Author keywords

Bioavailability; Dissolution; Fixed dose combination (FDC); Rifampicin; Tuberculosis

Indexed keywords

BUFFER; ETHAMBUTOL; HYDROCHLORIC ACID; ISONIAZID; PHOSPHATE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; VEGETABLE OIL;

AGITATION; ARTICLE; DISSOLUTION; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG DOSAGE FORM; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG RELEASE; DRUG STABILITY; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; MEDICAL LITERATURE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; STOMACH PH; TABLET FORMULATION; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG INDUSTRY; DRUG THERAPY, COMBINATION; HUMANS; PRODUCT PACKAGING; QUALITY CONTROL; RIFAMPIN; SOLUBILITY; TUBERCULOSIS, PULMONARY; WORLD HEALTH;

EID: 4444293226     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardized treatment regimens. Drugs 2003; 63: 535-553.
2. Acocella G. Human bioavailability studies. IUATLD Symposium. Quality control of anti-tuberculosis drugs. Dubrovnik, 6 October 1988. Bull Int Union Tuberc Lung Dis 1989; 64: 38-40.
3. Anonymous. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tubercle Lung Dis 1994; 75: 180-181.
4. Agrawal S, Panchagnula R. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. Int J Pharm (in press).
5. McIlleron H, Wash P, Burger A, Folb P, Smith P. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6: 356-361.
6. Pillai G, Fourie P B, Padyatchi N, et al. Recent bioequivalence studies on fixed dose combination anti-tuberculosis drug formulations available on the global market. Int J Tuberc Lung Dis 1999; 3 (Suppl 3): S309-8316.
7. Panchagnula R, Kaur K J, Singh I, Kaul C L. Bioequivalence of rifampicin when administered as a fixed-dose combination of four drugs versus separate formulations. Method Find Exp Clin Pharmacol 2000; 22: 689-694.
8. Agrawal S, Singh I, Kaur K J, Bhade S R, Kaul C L, Panchagnula R. Bioequivalence assessment of rifampicin, isoniazid, and pyrazinamide and ethambutol vs. separate formulations. Int J Clin Pharmacol Ther 2002; 40: 474-481.
9. United States Pharmacopoeia. Disintegration test. USP 24. Rockville, MD: United States Pharmacopoeial Convention, Inc, 2000: pp 1941.
10. United States Pharmacopoeia. Rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride tablets. USP 26. Rockville, MD: United States Pharmacopoeial Convention, Inc, 2003: pp 1645-1646.
11. United States Pharmacopoeia. Rifampicin capsules. USP 26, Rockville, MD: United States Pharmacopoeial Convention, Inc, 2003: pp. 1640-1641.
12. Panchagnula R, Rungta S, Sancheti P, Agrawal S, Kaul C L. In vitro evaluation of food effect on the bioavailability of rifampicin from anti tuberculosis fixed dose combination formulations. Il Farmaco 2003; 50: 1099-1103.
13. ICH harmonised tripartite guideline. Stability testing of new drug substances and products. ICH Steering Committee. 6th February, 2003. Brussels, Belgium. Geneva, Switzerland: ICH, 2003.
14. Solvang S, Finholt P. Effect of tablet processing and formulation factors of the active ingredient in human gastric juice. J Pharm Sci 1970; 59: 49-52.
15. Aspesi F. Dissolution testing. IUATLD Symposium. Quality control of anti-tuberculosis drugs. Dubrovnik, 6 October 1988. Bull Int Union Tuberc Lung Dis 1989; 64: 37-38.
16. Amidon G L, Lennernas H, Shah V P, Crison J R. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995; 12: 413-420.
17. Panchagnula R, Agrawal S. Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin. Int J Pharm 2004; 271; 1-4. [Review.]
18. Peloquin C A, Namdar R, Singleton M D, Nix D E. Pharmacokinetics of rifampicin under fasted conditions, with food, and with antacids. Clin Invest 1999; 115: 12-18.
19. Dressman J B, Amidon G L, Reppas C, Shah V P. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 1998; 15: 11-20.
20. Katori N, Aoyagi N, Terao T. Estimation of agitation intensity in the GI tract in humans and dogs based on in vitro/in vivo correlation. Pharm Res 1995; 12: 237-243.
21. Shah V P, Gurbarg M, Noory A, Dighe S, Skelly J P. Influence of higher rates of agitation on release patterns of immediate release drug products. J Pharm Sci 1992; 81: 500-503.
22. Galia E, Horton J, Dressman J B. Albendazole generics-a comparative in vitro study. Pharm Res 1999; 12: 1871-1875.
23. Risha P G, Vervaet C, Vergote G, Bortel L V, Remon J P. Drug formulations intended for the global market should be tested for stability under tropical climatic conditions. Eur J Clin Pharmacol 2003; 59: 135-141.
24. Grimm W. Extension of international conference on harmonization tripartite guideline for stability testing of new drug substances and products to countries of climatic zones III and IV. Drug Dev Ind Pharm 1998; 24: 313-325.
25. Singh S, Mohan B. A pilot stability study on four-drug fixed dose combination anti-tuberculosis products. Int J Tuberc Lung Dis 2003; 7: 298-303.
26. Maponga C, Ondari C. The quality of anti-malarials: a study in selected African countries. WHO/EDM/PAR/2003.4. Geneva, Switzerland: World Health Organization, 2003.
27. Agrawal S, Panchagnula R. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms. Die Pharmazie (2004) (article in press).